Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

NCT00631371 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

791

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Bevacizumab
DRUG: Temsirolimus
DRUG: Bevacizumab
DRUG: Interferon-Alfa 9MU

Sponsor

Pfizer